STOCK TITAN

LivaNova PLC (LIVN) Stock Price, News & Analysis

LIVN NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
6 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
+17.9% close of November 4, 2026
1-year change
+65.4% closing prices, November 13, 2025 to November 13, 2026
1-month change
+19.6% closing prices, October 13, 2026 to November 13, 2026

Company Description

LivaNova PLC (NASDAQ: LIVN) is a global medical technology company that focuses on select neurological and cardiac conditions. According to company disclosures, LivaNova is built on nearly five decades of experience and is driven by a vision to change the trajectory of patients’ lives. The company is headquartered in London and reports that it has a presence in more than 100 countries, serving patients, healthcare professionals, and healthcare systems worldwide.

LivaNova operates in the surgical and medical instrument manufacturing industry within the broader manufacturing sector. The company describes itself as a medical technology business that develops and provides medical technologies for neurological and cardiac conditions. Its activities include neuromodulation therapies and cardiopulmonary solutions, as reflected in its communications about epilepsy, obstructive sleep apnea, and heart-lung support technologies.

The firm’s heritage includes a combination of Cyberonics in the United States and Sorin in Italy, which formed the basis of today’s LivaNova. Historical descriptions note that the company has focused on cardiopulmonary solutions, such as heart-lung machines and oxygenation equipment, and neuromodulation devices for treatment-resistant epilepsy and depression. Over time, LivaNova has divested certain businesses, including cardiac rhythm management, heart valves, and extracorporeal membrane oxygenation, to concentrate on its chosen areas.

Neuromodulation and Epilepsy

A central area for LivaNova is neuromodulation for Drug-Resistant Epilepsy (DRE). The company highlights VNS Therapy™, an add-on treatment designed to reduce seizure frequency in adults and children as young as four years old with DRE and partial onset seizures. LivaNova describes VNS Therapy as a unique treatment approach developed for people with drug-resistant epilepsy. Company materials emphasize that implantation is an outpatient procedure that does not require penetration of the skull, distinguishing it from some other surgical treatment options.

LivaNova has sponsored the CORE-VNS study, which it describes as the largest prospective, multinational observational study of VNS Therapy for DRE. The company reports that CORE-VNS is a real-world, long-term, open-label study that enrolled more than 800 people at 61 sites worldwide. According to LivaNova, the study provides a comprehensive assessment of VNS Therapy effectiveness and offers modern insights into global use of the therapy in seizure management.

In its communications, LivaNova notes that real-world evidence from CORE-VNS demonstrates significant seizure reduction and improved outcomes for patients with DRE, including reductions in severe disabling seizures and decreases in rescue medication use over time. The company also references health economics analyses that examine healthcare resource use and costs before and after VNS Therapy implantation across different U.S. payer types, including commercial insurance, Medicare, and Medicaid.

Cardiopulmonary Business

LivaNova also operates a Cardiopulmonary business that it associates with heart-lung support during cardiac surgery. The company has discussed a global cardiopulmonary market and references its Essenz™ Perfusion System and related consumables in its public communications. LivaNova has indicated that this business participates in a large global market for cardiopulmonary products and that it seeks growth through equipment replacement cycles, consumables, and related offerings.

In recent updates, LivaNova has highlighted the commercial launch of the Essenz Perfusion System in additional geographies and has described demand for consumables that support the installed base. The cardiopulmonary segment is presented by the company as one of its core businesses and as a contributor to its overall revenue and operating performance.

Obstructive Sleep Apnea and Proximal Hypoglossal Nerve Stimulation

LivaNova is also active in the field of obstructive sleep apnea (OSA). The company is developing and studying a differentiated neurostimulation modality known as proximal hypoglossal nerve stimulation (p‑HGNS). This approach is associated with the aura6000™ System, which LivaNova describes as an investigational device for moderate to severe OSA in patients who have failed or are unwilling to use positive airway pressure treatment.

Through clinical studies such as THN‑3 and OSPREY, LivaNova and independent investigators have evaluated p‑HGNS, which utilizes six electrodes placed on the proximal trunk of the hypoglossal nerve. Company materials state that this configuration is intended to provide broad access to muscles controlling the airway and to enable customized titration. LivaNova has reported multi‑year analyses and 12‑month data showing improvements in sleep‑disordered breathing, oxygenation, and quality of life measures in patients with moderate to severe OSA.

Strategic Focus and Core Businesses

In its investor communications, LivaNova describes its strategy as building on leadership positions in Epilepsy and Cardiopulmonary while developing a pipeline in areas such as obstructive sleep apnea and difficult‑to‑treat depression. The company refers to its Epilepsy and Cardiopulmonary operations as core businesses that provide a foundation for growth, margin expansion, and cash generation.

LivaNova has presented a long‑range plan that emphasizes maximizing these core businesses, scaling its OSA program, and maintaining potential upside in difficult‑to‑treat depression as part of its neuromodulation platform. The company characterizes the OSA market as large and underpenetrated and points to clinical data and its differentiated technology as reasons it is pursuing this area.

Global Footprint and Stakeholders

LivaNova states that it employs approximately 2,900 to 3,000 people and has a presence in more than 100 countries. Its disclosures emphasize serving multiple stakeholder groups, including patients, healthcare professionals, hospitals, and healthcare systems. As a global medical technology company, LivaNova communicates regularly with investors through conference presentations, investor days, and quarterly results calls.

The company’s common shares trade on the NASDAQ under the ticker symbol LIVN. LivaNova is incorporated in England and Wales and files reports with the U.S. Securities and Exchange Commission, including Form 8‑K current reports on material events such as financial results and board appointments.

Regulatory and Clinical Evidence

Because LivaNova operates in regulated medical technology markets, clinical evidence and regulatory decisions are important to its activities. The company highlights data from large observational studies and randomized controlled trials related to its neuromodulation therapies. It also communicates about reimbursement developments, such as decisions by the U.S. Centers for Medicare & Medicaid Services (CMS) that affect provider payment levels for VNS Therapy procedures in drug‑resistant epilepsy.

In its public statements, LivaNova has described CMS actions that assign VNS Therapy procedures to specific ambulatory payment classifications and elevate certain procedures to higher payment levels. The company has indicated that these reimbursement changes are expected to improve hospital economics for Medicare procedures and reduce barriers to procedure penetration for eligible patients.

Company Identity and Purpose

Across its news releases and investor communications, LivaNova consistently describes itself as a global medical technology company with a focus on changing the trajectory of lives in select neurological and cardiac conditions. The company emphasizes its experience over nearly five decades, its London headquarters, and its worldwide presence. It positions its therapies as medical technologies intended to deliver life‑changing solutions for patients and their families.

Stock Performance

$91.32
+1.24%
+1.12
Last updated: November 13, 2026 at 16:00
+65.4%
Performance 1 year

LivaNova PLC (LIVN) closed at $91.32 on November 13, 2026. Over the past 12 months, the price has gained 65.4%.

See what a $1,000 investment in LIVN would be worth today

Average down calculator for LIVN

LIVN Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
9,950
Shares Sold
4
Transactions
Most Recent Transaction
Shvartsburg Alex (Chief Financial Officer) sold 2,500 shares @ $90.91 on November 12, 2026

Insider selling at LivaNova PLC over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

LivaNova PLC generated $1.4B in revenue in FY2025, retaining a 67.7% gross margin, operating income reached $199.4M (14.4% operating margin), and net income was -$242.5M, reflecting a -17.5% net profit margin. Diluted earnings per share stood at -$4.45. The company generated $254.3M in operating cash flow. The current ratio was 1.36, measuring current assets divided by current liabilities.

$1.4B
Revenue (FY2025)
-$242.5M
Net Income (FY2025)
$254.3M
Operating Cash Flow

Upcoming Events

NOV
17
November 17, 2026 Marketing

Jefferies fireside chat

Executive leadership fireside chat at Jefferies on Nov 17; webcast access via LivaNova website for registrants; replay available within 24h.
H1
2027
H1 2027 Product

Next-gen device commercialization

Target H1 2027 commercialization pending FDA supplement review; MRI-compatible, rechargeable device
YEAR
2027
2027 Product

Aura6000 commercial launch

Commercial launch of aura6000 System in 2027, contingent on PMA supplement approval; timing subject to FDA decision.
YEAR
2027
2027 Product

U.S. OSA product launch

Independent U.S. commercial launch of OSA device planned

LivaNova PLC has 4 upcoming scheduled events. The next event, "Jefferies fireside chat", is scheduled for November 17, 2026 (tomorrow). Investors can track these dates to stay informed about potential catalysts that may affect the LIVN stock price.

Short Interest History

Last 12 Months

Short interest in LivaNova PLC (LIVN) currently stands at 6.4 million shares, up 2.6% from the previous reporting period, representing 11.6% of the float. Since November 2025, short interest has increased by 177.6%.

Days to Cover History

Last 12 Months

Days to cover for LivaNova PLC (LIVN) currently stands at 12.4 days, up 17.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 209%. Across the settlements charted above, it has ranged from 2.4 to 12.4 days.

LIVN Company Profile & Sector Positioning

LivaNova PLC (LIVN) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing LIVN often look at related companies in the same sector, including Haemonetics Corporation (HAE), Integer Holdings Corporation (ITGR), iRhythm Holdings, Inc. (IRTC), 10x Genomics, Inc. (TXG), and Axogen, Inc. (AXGN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate LIVN's relative position within its industry.

Frequently Asked Questions

The current stock price of LivaNova PLC (LIVN) is $91.32 as of November 13, 2026.

The market cap of LivaNova PLC (LIVN) is approximately $5.0B. Learn more about what market capitalization means .

The FY2025 revenue of LivaNova PLC (LIVN) is $1.4B, from its most recent completed fiscal year.

The FY2025 net income of LivaNova PLC (LIVN) is -$242.5M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of LivaNova PLC (LIVN) is -$4.45 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of LivaNova PLC (LIVN) is $254.3M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of LivaNova PLC (LIVN) is -17.5% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of LivaNova PLC (LIVN) is 14.4% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of LivaNova PLC (LIVN) is 67.7% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of LivaNova PLC (LIVN), current assets divided by current liabilities, was 1.36 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of LivaNova PLC (LIVN) is $939.9M for FY2025, its most recent completed fiscal year.

The operating income of LivaNova PLC (LIVN) is $199.4M for FY2025, its most recent completed fiscal year. Learn about operating income.